These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 16203151)
1. The benefits of the multi-target approach in drug design and discovery. Espinoza-Fonseca LM Bioorg Med Chem; 2006 Feb; 14(4):896-7. PubMed ID: 16203151 [TBL] [Abstract][Full Text] [Related]
2. Fragments, network biology and designing multiple ligands. Morphy R; Rankovic Z Drug Discov Today; 2007 Feb; 12(3-4):156-60. PubMed ID: 17275736 [TBL] [Abstract][Full Text] [Related]
3. Importance of molecular computer modeling in anticancer drug development. Geromichalos GD J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268 [TBL] [Abstract][Full Text] [Related]
4. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. Zhao H Drug Discov Today; 2007 Feb; 12(3-4):149-55. PubMed ID: 17275735 [TBL] [Abstract][Full Text] [Related]
5. Screening the receptorome: an efficient approach for drug discovery and target validation. Strachan RT; Ferrara G; Roth BL Drug Discov Today; 2006 Aug; 11(15-16):708-16. PubMed ID: 16846798 [TBL] [Abstract][Full Text] [Related]
6. Natural product hybrids as new leads for drug discovery. Tietze LF; Bell HP; Chandrasekhar S Angew Chem Int Ed Engl; 2003 Sep; 42(34):3996-4028. PubMed ID: 12973759 [TBL] [Abstract][Full Text] [Related]
7. High-throughput assays for promiscuous inhibitors. Feng BY; Shelat A; Doman TN; Guy RK; Shoichet BK Nat Chem Biol; 2005 Aug; 1(3):146-8. PubMed ID: 16408018 [TBL] [Abstract][Full Text] [Related]
8. Predicting the multi-modal binding propensity of small molecules: towards an understanding of drug promiscuity. Park K; Lee S; Ahn HS; Kim D Mol Biosyst; 2009 Aug; 5(8):844-53. PubMed ID: 19603120 [TBL] [Abstract][Full Text] [Related]
9. Screening for transient biological interactions as applied to albumin ligands: a new concept for drug discovery. Ohlson S; Shoravi S; Fex T; Isaksson R Anal Biochem; 2006 Dec; 359(1):120-3. PubMed ID: 17052679 [TBL] [Abstract][Full Text] [Related]
10. The impact of molecular biology on drug discovery. Belfield GP; Delaney SJ Biochem Soc Trans; 2006 Apr; 34(Pt 2):313-6. PubMed ID: 16545102 [TBL] [Abstract][Full Text] [Related]
11. Fragment-based drug design: combining philosophy with technology. Bartoli S; Fincham CI; Fattori D Curr Opin Drug Discov Devel; 2007 Jul; 10(4):422-9. PubMed ID: 17659483 [TBL] [Abstract][Full Text] [Related]
12. Fragment-based ligand discovery. Fischer M; Hubbard RE Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661 [TBL] [Abstract][Full Text] [Related]
13. Metal complexes in medicinal chemistry: new vistas and challenges in drug design. Thompson KH; Orvig C Dalton Trans; 2006 Feb; (6):761-4. PubMed ID: 16437168 [TBL] [Abstract][Full Text] [Related]
17. I want a new drug: G-protein-coupled receptors in drug development. Schlyer S; Horuk R Drug Discov Today; 2006 Jun; 11(11-12):481-93. PubMed ID: 16713899 [TBL] [Abstract][Full Text] [Related]
18. The modular approach to ligand discovery. Karan C; Tallarico JA Chem Biol; 2004 Mar; 11(3):292-3. PubMed ID: 15123257 [TBL] [Abstract][Full Text] [Related]
19. Structural basis for ligand recognition at the benzodiazepine binding site of GABAA alpha 3 receptor, and pharmacophore-based virtual screening approach. Vijayan RS; Ghoshal N J Mol Graph Model; 2008 Oct; 27(3):286-98. PubMed ID: 18565775 [TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]